1. Home
  2. EVI vs ADCT Comparison

EVI vs ADCT Comparison

Compare EVI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EVI Industries Inc.

EVI

EVI Industries Inc.

SELL

Current Price

$20.01

Market Cap

204.6M

ML Signal

SELL

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

SELL

Current Price

$1.29

Market Cap

192.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EVI
ADCT
Founded
1959
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.6M
192.7M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
EVI
ADCT
Price
$20.01
$1.29
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
92.8K
★ 1.2M
Earning Date
11-09-2026
11-09-2026
Dividend Yield
★ 1.58%
N/A
EPS Growth
N/A
★ 30.86
EPS
★ 0.24
N/A
Revenue
★ $389,830,000.00
$81,357,000.00
Revenue This Year
$8.40
N/A
Revenue Next Year
$4.71
$25.89
P/E Ratio
$87.00
★ N/A
Revenue Growth
10.26
★ 14.85
52 Week Low
$12.75
$0.78
52 Week High
$27.00
$4.98

Technical Indicators

Market Signals
Indicator
EVI
ADCT
Relative Strength Index (RSI) 44.93 42.68
Support Level $19.93 $0.97
Resistance Level $21.37 $1.45
Average True Range (ATR) 1.50 0.17
MACD -0.28 -0.04
Stochastic Oscillator 6.35 9.60

Price Performance

Historical Comparison
EVI
ADCT

About EVI EVI Industries Inc.

EVI Industries Inc is a value-added distributor and service provider in the commercial laundry industry. It sells and leases commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company supports its equipment offerings with installation, maintenance, and repair services through a large network of trained technicians. It serves a wide range of customers, including commercial, industrial, institutional, government, and retail sectors. Geographically, the company serves various countries including United States, Canada, the Caribbean, and Latin America.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: